The research status of TB-500 can be summarized in four key points:
1. Animal data support
Philp et al. (2003) demonstrated wound-healing activity for the seven-amino-acid fragment itself. This is the closest study to TB-500’s actual profile, but it is not a human trial.
2. Missing human data
TB-500 has not been tested in human clinical trials. The human data cited in support of TB-500 comes mainly from full-length Tβ4 studies.
3. Evidence transfer controversy
When a study reports that Tβ4 accelerated wound healing, reduced cardiac fibrosis, or promoted corneal repair, that finding cannot be directly transferred to injectable TB-500. The mechanism overlaps in the actin-binding domain, but the full protein has functional domains the fragment lacks.
4. New metabolite finding
A 2024 study by Rahaman et al. found that TB-500 rapidly breaks down into Ac-LKKTE, suggesting the active molecule may be neither TB-500 nor full-length Tβ4. This finding has not been independently confirmed.
Future research directions
Human clinical trials
Independent confirmation of the Rahaman 2024 finding
Determining which Tβ4 functions the fragment retains
Evaluating long-term safety
Conclusion
TB-500 research is still ongoing. It may provide valuable clues for wound-healing research, but at this stage it is better viewed as an unverified synthetic fragment rather than a mature therapy.